Clinical Trial Update: Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update comparing pembrolizumab given every 12 weeks versus every 3 weeks in patients with non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Lung Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING